New oral anticoagulants - a practical guide

Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery
Tomasz CiurusMalgorzata Lelonek

Abstract

Oral direct inhibitors of thrombin and activated factor Xa are approved as new anticoagulant drugs. In contrast to vitamin K antagonists (VKA) and heparins, the new agents have single targets in the coagulation cascade and more predictable pharmacokinetics, but they lack validated and available antidotes. Unlike VKA, they do not require routine monitoring of coagulation. However, the measurement of their pharmacologic effects might be of value in selected patients. They interfere with the routine coagulation tests, which should be interpreted with caution. Specific tests exist and can be used in case of emergencies. Adequate supportive care and temporary removal of all antithrombotic agents constitute the basis for management of serious bleeding complications. The administration of coagulation factors, such as fresh frozen plasma, prothrombin complex concentrates or recombinant activated FVII, can benefit in life-threatening bleeding or emergency surgery. Specific antidotes for non-vitamin K oral anticoagulants are in clinical development. This review aims at answering in a brief and simplified manner some clinical questions.

Citations

Jan 20, 2019·Journal of Personalized Medicine·Sri H Kanuri, Rolf P Kreutz
Jun 25, 2019·JAMA Internal Medicine·Namrah SiddiqSung-Hee Choi
Apr 2, 2020·Advances in Hematology·Mark Terence P MujerPrajwal Dhakal

❮ Previous
Next ❯

Software Mentioned

TOAT

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

© 2021 Meta ULC. All rights reserved